Miza III investor SciSparc acquires 63.3 million shares

Executive Summary

• SciSparc Ltd. acquired approximately 63.3 million common shares (≈75% non‑diluted, 84.53% partially diluted) of Neurothera Labs Inc., together with four million purchase warrants and 48 million contingent rights.
• The acquisition was made in connection with a reverse takeover that transferred all SciSparc Nutraceuticals Inc. shares (50.86% of SNI) and certain assets to Neurothera Labs.
• The transaction triggers an early‑warning filing under applicable securities laws; SciSparc states the holdings are for investment purposes with no immediate plans to buy or sell additional securities.

Key Details

• Shares Acquired: 63.3 million common shares of Neurothera Labs Inc. (formerly Miza III Ventures Inc.).
• Warrants Acquired: Four million common share purchase warrants, exercisable at US $0.25 per share through 22 Oct 2030.
• Contingent Rights: 48 million contingent rights, each convertible into one share upon achievement of predetermined milestones.
• Ownership Percentage Post‑Transaction: ~75% on a non‑diluted basis; ~84.53% on a partially diluted basis.
• Deemed Share Value: US $0.25 per common share (used for early‑warning reporting).
• Purpose of Holdings: Investment; no current plan to acquire additional securities or dispose of existing holdings, though future actions may occur based on market conditions or strategic considerations.
• Regulatory Filing: Early warning report filed as required; available via SEDAR+ or directly from SciSparc (phone: 972‑3‑610‑3100; email: [email protected]).

Notable Quotes

(No direct quotes were provided in the release.)